Alkermes plc. Business Combination, Contingent Consideration, Asset, Current
Alkermes plc. (ALKS) had Business Combination, Contingent Consideration, Asset, Current of $3.80 million as of 2022-06-30, per its 10-Q filed 2022-07-27.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:BusinessCombinationContingentConsiderationAssetCurrent · last filed 2022-11-02
- 2022-06-30: Business Combination, Contingent Consideration, Asset, Current $3.80M.
- 2022-03-31: Business Combination, Contingent Consideration, Asset, Current $3.40M.
- 2021-12-31: Business Combination, Contingent Consideration, Asset, Current $6.40M.
- 2021-09-30: Business Combination, Contingent Consideration, Asset, Current $6.40M.
| Period end | Business Combination, Contingent Consideration, Asset, Current |
|---|---|
| 2022-06-30 | $3.80M 10-Q · filed 2022-07-27 |
| 2022-03-31 | $3.40M 10-Q · filed 2022-04-27 |
| 2021-12-31 | $6.40M 10-Q · filed 2022-11-02 |
| 2021-09-30 | $6.40M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $6.50M 10-Q · filed 2021-07-28 |
| 2021-03-31 | $7.90M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $7.80M 10-K · filed 2022-02-16 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |